Related Experiment Video
Updated: May 16, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Topical imiquimod and in situ vulvar melanoma: A promising therapy?
Francesca Pepe1, Flavia Silvestri1, Eleonora Petra Preti2
1Dermato-Oncology Unit, European Institute of Oncology IRCCS, Milan, Italy.
Objectives:
Vulvar melanoma is a rare type of cancer that affects mainly postmenopausal women. There are no established protocols for the treatment of vulvar melanoma. From data extrapolated from the literature on cutaneous melanoma, surgical excision remains the best option for the resectable disease. Imiquimod, a topical immunomodulator, has been used in selected cases of in situ vulvar melanoma.
Methods And Results:
We reported two cases of in situ vulvar melanoma treated with topical imiquimod 5%, either as first-line therapy or adjuvant treatment, that showed a complete clinical response to topical treatment.
Conclusion:
Imiquimod's beneficial and adverse effects in in situ vulvar melanoma treatment are examined.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy

